S 637880
Alternative Names: S-637880Latest Information Update: 30 Dec 2021
At a glance
- Originator Shionogi
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuropathic pain
Most Recent Events
- 01 Nov 2021 Phase-II clinical trials in Neuropathic pain in Japan (PO) before November 2021 (Shionogi's pipeline, November 2021)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Neuropathic-pain in Japan (PO)
- 15 May 2018 Shionogi plans a phase II trial for Neuropathic pain in 2021